Iovance Biotherapeutics Inc (IOVA) Q3 2024 Earnings Call Highlights: Surpassing Revenue ...

Iovance Biotherapeutics Inc (IOVA) Q3 2024 Earnings Call Highlights: Surpassing Revenue ...

Frederick Vogt discusses IL-2 stocking levels with potential growth in 2025 due to steady numbers from major U.S. distributors. Improved manufacturing processes lead to increased comfort with preconditioning at ATCs. Month-over-month infusion growth is driven by manufacturing capacity and demand.

Read More

Did you find this insightful?